Use of a modified dosing weight for heparin therapy in a morbidly obese patient

Annals of Pharmacotherapy

Volumn 39, Issue 4, 2005, Pages 753-756

  Schwiesow, Sarah J ^a   Wessell, Andrea M ^b   Steyer, Terrence E ^b  

^a KAISER PERMANENTE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Anticoagulation; Heparin; Morbid obesity; Pulmonary embolism

Indexed keywords

ALLOPURINOL; FUROSEMIDE; GLYCERYL TRINITRATE; HEPARIN; OXAPROZIN; SPIRONOLACTONE;

ADULT; ANTICOAGULATION; ARTICLE; BODY WEIGHT; CASE REPORT; CONTINUOUS INFUSION; DOSE CALCULATION; DYSPNEA; FEMALE; HEPARINIZATION; HUMAN; LUNG EMBOLISM; OBESITY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; TACHYCARDIA; THORAX PAIN;

BODY WEIGHT; FEMALE; HEPARIN; HUMANS; MIDDLE AGED; OBESITY, MORBID; PULMONARY EMBOLISM;

EID: 15444366101     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E300     Document Type: Article

References (13)

1. Kroegel C, Reissig A. Principle mechanisms underlying thromboembolism: epidemiology, risk factors, pathophysiology and pathogenesis. Respiration 2003;70:7-30.
2. Romaisa F, Elamin EM. Recent advances in pulmonary embolism diagnosis and management. Comp Ther 2001;27:156-62.
3. Hyers TM. Management of venous thromboembolism. Arch Intern Med 2003;163:759-68.
4. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin. Chest 2001;119(suppl 1):64-94.
5. Kandrotas RJ. Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1992;22:359-74.
6. Raschke RA, Brendan MR, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a standard care nomogram. Ann Intern Med 1993;119:874-81.
7. Spruill WJ, Wade WE, Huckaby G, Leslie RB. Achievement of anticoagulation by using weight-based heparin dosing protocol for obese and nonobese patients. Am J Health Syst Pharm 2001;15:2143-6.
8. Ellison MJ, Sawyer WT, Mills TC. Calculation of heparin dosage in a morbidly obese woman. Clin Pharm 1989;8:65-8.
9. Yee WP, Norton LL. Optimal weight base for a weight-based heparin dosing protocol. Am J Health Syst Pharm 1998;55:159-62.
10. Ginsberg JS. Management of venous thromboembolism. N Engl J Med 1996;335:1816-28.
11. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin. Chest 2004;126(suppl 3):188-203.
12. Beermann B, Lahnborg G. Pharmacokinetics of heparin in healthy and obese subjects and in combination with dihydroergotamine. Thromb Haemost 1981;45:24-6.
13. Rosborough TK, Shepherd MF. Achieving target antifactor Xa activity with a heparin protocol based on sex, age, height and weight. Pharmacotherapy 2004;24:713-9.